GeneDx Shares Plunge 14% After 2025 Results, Forecasts 33-35% Testing Volume Growth
GeneDx's preliminary full-year 2025 results met guidance but fell short of expectations, prompting a 14% stock decline on Monday. The company forecast 33-35% testing volume growth for 2026, which investors regarded as too conservative for a high-growth biotech, eroding near-term momentum.
1. Q4 Results Meet Guidance, Triggering Pullback
GeneDx reported preliminary fourth-quarter results in line with its internal targets, delivering testing volumes that tracked management’s forecast. Although the company did not miss its projections, the lack of an upside surprise was insufficient to support the lofty multiples assigned to high-growth genomics peers. On Monday, WGS shares declined by 14%, as investors rotated out following the confirmation that revenue growth would merely match, rather than exceed, expectations for the period.
2. Monday’s 14% Stock Decline Highlights Sentiment Sensitivity
The abrupt share price drop underscores the market’s heightened sensitivity to growth biotech earnings that merely meet, rather than beat, consensus forecasts. Trading volume on Monday spiked to nearly three times the ten-day average, suggesting that both institutional and retail holders adjusted positions quickly. Analysts at two major brokerages lowered their near-term target prices, citing a recalibration of valuation multiples given the temporary pause in momentum.
3. 2026 Guidance Projects Robust 33–35% Volume Growth
Despite the near-term share volatility, GeneDx issued full-year 2026 guidance that calls for testing volume growth of 33–35%, outpacing the mid-20% average expansion rate projected by consensus models. Management highlighted pipeline enhancements in exome and genome sequencing for rare disease diagnostics, as well as the integration of newly acquired bioinformatics assets. The company reiterated its goal of driving operating leverage, targeting a mid-teens operating margin by year-end 2026.
4. Leadership in Rare Disease Testing Supports Long-Term Outlook
With one of the industry’s most comprehensive rare disease variant databases—now exceeding 500,000 unique exomes—GeneDx is positioned to capitalize on accelerating adoption of precision diagnostics. The firm’s direct-to-physician lab network expanded to over 1,200 hospital systems last quarter, and recent partnerships with three major pediatric health centers are expected to add approximately 20,000 incremental tests annually. These strategic initiatives underpin management’s confidence in returning to sustained double-digit stock appreciation once quarterly comparisons normalize.